Mitoxantrone metabolism in the isolated perfused rat liver
Authors:
- 1 January 1984
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 12 (1) , 50-52
Abstract
The hepatobiliary pharmacokinetics of mitoxantrone, a new anthracenedione derivative, was studied in the isolated perfused rat liver. Mitoxantrone was administered in doses of 0.2 and 0.4 mg/kg body weight. Multiple bile samples were obtained for 4 hours. Mitoxantrone and three metabolites were separated by high-performance thin-layer chromatography (HPTLC) and measured at 610 nm. Following 0.2 mg mitroxantrone/kg body wt, 25.8%±2.6% of the administered dose was excreted in the bile during 4 h, the major metabolite M1 accounting for 80% of this. After 0.4 mg mitoxantrone/kg body wt the amounts excreted were lower and light microscopic examination showed disseminated areas of cell necrosis.Keywords
This publication has 5 references indexed in Scilit:
- Clinical analysis for the anti-neoplastic agent 1,4-dihydroxy-5,8-bis{{2-[(2-hydroxyethyl)amino]ethyl}amino} 9,10-anthracenedione dihydrochloride (NSC 301739) in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1981
- Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.1980
- Phase I clinical trial of mitoxantrone: A new anthracenedione anticancer drugCancer Chemotherapy and Pharmacology, 1980
- Activity and stability of microsomal mixed function oxidase and NAD glycohydrolase in isolated perfused rat liverNaunyn-Schmiedeberg's Archives of Pharmacology, 1972
- THE DOMINANT ROLE OF THE LIVER IN PLASMA PROTEIN SYNTHESISJournal of Experimental Medicine, 1951